#96 Calcitonin withdrawal: Now what for acute vertebral fractures?
CLINICAL QUESTION
Is there any medication (other than traditional analgesia) that works for bone pain resulting from osteoporotic vertebral compression fractures (OVCF)?
BOTTOM LINE
Calcitonin had weak evidence of moderate effectiveness for acute OVCF pain but was withdrawn over cancer risks. Although the evidence is very poor, bisphosphonates appear to have similar effect on acute pain reduction and are useful in secondary fracture prevention
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
As of October 1, 2013, Synthetic Calcitonin (Salmon) nasal spray will be withdrawn from the Canadian Market.1 Despite being on the market since 1975 (in the U.S.), only recently has a meta-analysis of 17 Randomized Controlled Trials (RCTs) concluded that calcitonin is associated with an increased risk of overall malignancy with a Number Needed to Harm (NNH) of 63.2
- A systematic review of five RCTs (246 patients) demonstrated that calcitonin was effective in reduction of OVCF pain compared to placebo with a mean difference (MD) of 3.4 on a 10 point visual analogue scale (VAS) at one week.3
- Two small studies examining bisphosphonates for pain.
- One direct comparison RCT: 27 women, IV pamidronate or IV calcitonin x 1 dose4
- Day 4: both groups had statistically significant improvement in pain on VAS scale:
- • Pamidronate ~1.1 (baseline 5.9)
- • Calcitonin ~2.3 (baseline 6.3)
- ▪ Day 30: Pamidronate ~2.3cm, Calcitonin ~3.1cm
- No statistically significant difference in pain scores, functional disability or analgesic use
- Day 4: both groups had statistically significant improvement in pain on VAS scale:
- o RCT 32 women, IV pamidronate versus placebo (baseline ~7.6)5
- After one week, those taking pamidronate had significantly decreased pain with standing (MD ~2.3) but not in supine pain (MD ~1.1)
- One direct comparison RCT: 27 women, IV pamidronate or IV calcitonin x 1 dose4
- The minimum clinically significant change in patient’s pain severity measured with a 10-cm VAS is 1.3 cm.6
- • Approximately 60% of patients with OVCF who are conservatively managed will have adequate resolution of pain within three months.7
- For secondary prevention, bisphosphonates are beneficial in prevention of vertebral (NNT 9-60) and non-vertebral fractures (NNT 20-68).8
- Bisphosphonates (oral and IV) have also demonstrated benefit in metastatic bone pain.9
- There is no evidence of superiority of one bisphosphonate over another in acute pain management.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
